Zifan Li

Dr. Zifan Li


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYunsa Huo
Yunsa Huo
PYPeng Yu
Peng Yu
TWTianye Wang
Tianye Wang
SYShihua Yang
Shihua Yang
PHPeng Han
Peng Han
ZLZifan Li
Zifan Li
Albumin-bound paclitaxel (Abraxane) exhibits potent antitumor activity, but its suboptimal pharmacokinetics and the restrictive blood-brain barrier (BBB) greatly limit the broader application of albumin-based paclitaxel formulations in intracranial tumors. In this work, we engineered size-uniform (~ 160 nm) paclitaxel-albumin nanoparticles (Fe3+@SA-PTX) via simple one-step nano-precipitation method guided by a “protein corona intervention” strategy. During nanoparticle fabrication, tannic acid-Fe3+ (TA-Fe3+) were strategically introduced. On the one hand, the introduction of TA-Fe3+ shell could slow down the leakage of paclitaxel and improving the stability and pharmacokinetic profile of the nanoparticles. On the other hand, the presence of Fe3+ enabled the nanoparticles to interact with unsaturated transferrin in plasma, forming a stable transferrin protein corona. This endowed the nanoparticles with enhanced tumor-targeting capability and the ability to penetrate the BBB. The Fe3+@SA-PTX exhibited superior pharmacokinetics and therapeutic efficacy against intracranial tumors via intravenous administration.

9 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZLZifan Li
Zifan Li
SYShihua Yang
Shihua Yang
LSLi-da Su
Li-da Su
The development of drug delivery systems for the treatment of intracranial central nervous system (CNS) diseases remains one of the most intractable medical problems in modern society, owing to the special physiological structure of the brain, including the existence of the blood-brain barrier (BBB), the CNS’s immune privilege, and its high complexity and vulnerability. Recently, a leading approach in the CNS drug delivery domain has been to employ or simulate the physiological behavior of microorganisms to overcome the BBB and remodel the pathological immune microenvironment in intracranial tissue. Considering the exceptional advancements in microorganism-based CNS drug delivery systems, it is imperative to review the latest breakthroughs. Herein, we summarize the emerging trends at the intersection of microorganism-based drug delivery systems and emerging biomedical technology for the treatment of CNS diseases, with a particular focus on preclinical research into microorganism-based drug delivery systems to combat CNS diseases, aiming to describe a credible landscape for further clinical trials.